We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Mood, side-effects and smoking outcomes among persons with and without probable lifetime depression taking varenicline.
- Authors
McClure, Jennifer B.; Swan, Gary E.; Jack, Lisa; Catz, Sheryl L.; Zbikowski, Susan M.; McAfee, Tim A.; Deprey, Mona; Richards, Julie; Javitz, Harold
- Abstract
<bold>Background: </bold>Varenicline may be associated with greater mood disturbance and side-effects among smokers with psychiatric history, but empirical evidence is limited. Differential treatment effectiveness by psychiatric history may also exist.<bold>Objective: </bold>To compare mood, prevalence and intensity of treatment side-effects, and abstinence among people with a probable history of major depression (DH+) or not (DH-) who took varenicline and received behavioral smoking cessation treatment.<bold>Design: </bold>Smokers participated in a randomized behavioral intervention effectiveness trial. Treatment side-effects and outcomes were compared between DH+ and DH- participants (n = 1,117) at 21 [corrected] days and 3 months after the target quit date.<bold>Participants: </bold>Smokers recruited from a large regional health plan.<bold>Measurements: </bold>Change in stress and depression scores, prevalence and intensity of treatment side-effects, and abstinence rates.<bold>Results: </bold>All side-effects averaged moderate intensity or less and were similar across DH groups, except DH+'s endorsed slightly worse confusion, nausea (adjusted P = 0.04) and trouble sleeping (adjusted P = 0.008) at 21 days. Depression and stress scores declined in both DH groups and an equal proportion of each evidenced new/worsening depressive symptoms. Despite few differences in symptom intensity, more DH+ participants reported recent tension/agitation, irritability/anger, confusion, and depression at 21 days (adjusted P < 0.05), and depression and anxiety (adjusted P < 0.01) at three months. Nonsmoking rates did not differ by DH group at follow-up.<bold>Conclusion: </bold>While some group differences were noted, DH+ smokers did not report qualitatively worse neuropsychiatric symptoms, more new/worsening mood disturbance, or differential abstinence rates compared to DH- smokers.
- Subjects
NICOTINE addiction treatment; NICOTINIC receptors; CHEMICAL agonists; SMOKING; THERAPEUTICS
- Publication
JGIM: Journal of General Internal Medicine, 2009, Vol 24, Issue 5, p563
- ISSN
0884-8734
- Publication type
journal article
- DOI
10.1007/s11606-009-0926-8